CARGO TherapeuticsCRGX
Market Cap: $865M
About: Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
Employees: 150
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]
94% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 16
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
12% more funds holding
Funds holding: 65 [Q1] → 73 (+8) [Q2]
2.59% more ownership
Funds ownership: 92.54% [Q1] → 95.13% (+2.59%) [Q2]
12% less capital invested
Capital invested by funds: $813M [Q1] → $716M (-$96.4M) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
HC Wainwright & Co. Robert Burns 39% 1-year accuracy 56 / 143 met price target | 75%upside $33 | Buy Reiterated | 13 Aug 2024 |
Piper Sandler Biren Amin 57% 1-year accuracy 8 / 14 met price target | 80%upside $34 | Overweight Maintained | 13 Aug 2024 |
HC Wainwright & Co. Robert Burns 39% 1-year accuracy 56 / 143 met price target | 75%upside $33 | Buy Initiated | 22 Jul 2024 |
Chardan Capital Geulah Livshits 11% 1-year accuracy 2 / 19 met price target | 49%upside $28 | Buy Initiated | 8 Jul 2024 |
Piper Sandler Biren Amin 57% 1-year accuracy 8 / 14 met price target | 96%upside $37 | Overweight Initiated | 27 Jun 2024 |